Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.2 EUR | -5.31% | +3.78% | +72.07% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.07% | 1.76B | |
+19.24% | 125B | |
+14.24% | 108B | |
-4.00% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-12.43% | 16.5B | |
+2.50% | 13.39B | |
+27.27% | 11.1B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target